{"entity":{"id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","aka":[],"tldr":"A phase 1/2 trial of TORL-5-700 in non-Hodgkin lymphoma, run by TORL Biotherapeutics, LLC, now recruiting.","summary":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT07439653 by TORL Biotherapeutics, LLC, with 155 participants planned, started 2026-03-31 and due to reach its primary completion in 2029-03-31. Interventions recorded: TORL-5-700, TORL-5-700 at MTD/RP2D and TORL-5-700 at MTD/RP2D in combination with another agent.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07439653","url":"https://clinicaltrials.gov/study/NCT07439653"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07439653","phase":"1/2","setting":"A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","sponsor":"TORL Biotherapeutics, LLC","enrolled":155,"outcomes":[]},"route":"/trials/nct07439653/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}